Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0JTPYN)
| ADC Name |
JP2025011033A Ab3
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
Ab3
Click to Show/Hide
|
|||||
| Organization |
ELI LILLY AND COMPANY
|
|||||
| Drug Status |
Investigative
|
|||||
| Antibody Name |
Ab3
|
Antibody Info | ||||
| Antigen Name |
Nectin-4 (NECTIN4)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Mean tumor colume±SEM |
366.45䕃.56
|
mm3
|
Undisclosed | Undisclosed |
| Mean tumor colume±SEM |
993.45𫐥.2
|
mm3
|
Undisclosed | Undisclosed |
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Mean tumor colume±SEM | 366.45䕃.56 mm3 | Moderate nectin-4 expression (nectin-4++) | ||
| Method Description |
Female NSG mice between 5-6 weeks of age were injected subcutaneously withMDA-MB-468 cells with moderate nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 71.
Click to Show/Hide
|
||||
| In Vivo Model | MDAMB468 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Mean tumor colume±SEM | 993.45𫐥.2 mm3 | High nectin-4 expression (nectin-4 +++) | ||
| Method Description |
Immune compromised female mice between 5-8 weeks of age with weight 18-20 grams were implanted unilaterally on the right flank with UM-UC-3 Nectin4 clone F7 cells with high nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 40.
Click to Show/Hide
|
||||
| In Vivo Model | UMUC3 Nectin-4 clone F7 xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.0553 nM | Positive nectin-4 expression (nectin-4+++/++) | ||
| Method Description |
ADCs were tested in NCI H1781 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H1781 cells | CVCL_1494 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.0825 nM | Positive nectin-4 expression (nectin-4+++/++) | ||
| Method Description |
ADCs were tested in T24-human nectin-4 clone 108 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
|
||||
| In Vitro Model | Bladder carcinoma | T24-human nectin-4 clone cells | CVCL_0554 | ||